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ORIGINAL ARTICLE
Cost-Effectiveness of Initiating Pharmacological 
Treatment in Stage One Hypertension Based on 
10-Year Cardiovascular Disease Risk
A Markov Modeling Study
Margaret Constanti , Christopher N. Floyd , Mark Glover, Rebecca Boffa, Anthony S. Wierzbicki ,* Richard J. McManus*
ABSTRACT: Antihypertensive drug treatment is cost-effective for adults at high risk of developing cardiovascular disease (CVD). 
However, the cost-effectiveness in people with stage 1 hypertension (140–159 mm Hg systolic blood pressure) at lower 
CVD risk remains unclear. The objective was to establish the 10-year CVD risk threshold where initiating antihypertensive 
drug treatment for primary prevention in adults, with stage 1 hypertension, becomes cost-effective. A lifetime horizon Markov 
model compared antihypertensive drug versus no treatment, using a UK National Health Service perspective. Analyses were 
conducted for groups ranging between 5% and 20% 10-year CVD risk. Health states included no CVD event, CVD and 
non-CVD death, and 6 nonfatal CVD morbidities. Interventions were compared using cost-per-quality-adjusted life-years. The 
base-case age was 60, with analyses repeated between ages 40 and 75. The model was run separately for men and women, 
and threshold CVD risk assessed against the minimum plausible risk for each group. Treatment was cost-effective at 10% 
CVD risk for both sexes (incremental cost-effectiveness ratio £10 017/quality-adjusted life-year [$14 542] men, £8635/
QALY [$12 536] women) in the base-case. The result was robust in probabilistic and deterministic sensitivity analyses but 
was sensitive to treatment effects. Treatment was cost-effective for men regardless of age and women aged >60. Initiating 
treatment in stage 1 hypertension for people aged 60 is cost-effective regardless of 10-year CVD risk. For other age 
groups, it is also cost-effective to treat regardless of risk, except in younger women. (Hypertension. 2020;77:00-00. DOI: 
10.1161/HYPERTENSIONAHA.120.14913.) • Data Supplement
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Hypertension is one of the most important reversible risk factors for global morbidity and mortality.1 Phar-macological treatment of hypertension reduces all-
cause mortality and incidence of cardiovascular disease 
(CVD) events, including heart attacks and strokes.2
Recommendations for antihypertensive drug treat-
ment in England are based, wherever possible, on 
the cost-effectiveness of treatment, with a threshold 
of <£20 000/quality-adjusted life-year (≈$29 000/
QALY).3,4 Previous UK National Institute for Health and 
Care Excellence (NICE) guidance for treatment initiation 
in those with stage 1 hypertension was consensus-
based and suggested treatment for those aged under 
80 with a 10-year CVD risk of 20% or greater.5
The systematic review comparing antihypertensive 
drug treatment at different blood pressure (BP) thresh-
olds, undertaken as part of updating the NICE hyper-
tension in adults guideline,6 showed a reduction in CVD 
events from antihypertensive treatment for people with 
stage 1 hypertension (clinic BP 140–159/90–99 
mm Hg). However, uncertainty remained about the cost-
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lower absolute risk levels, the number needed to treat 
was higher, and the balance of benefits and risks varied 
with different CVD risk levels.
In providing evidence for the 2019 NICE hyper-
tension guideline, this study aimed to establish the 
10-year CVD risk level at which initiation of antihyper-
tensive treatment in people with stage 1 hypertension 
was cost-effective.
METHODS
Data used in the study was sourced from the literature as cited.
A lifetime cost-utility analysis assessed the risk thresh-
old at which antihypertensive treatment of stage 1 hyper-
tension became cost-effective. A Markov model was 
developed for the National Health Service, comparing drug 
versus no drug treatment in people aged 40 and over. The 
model is briefly described below, with further technical 
details of the modeling available in the Data Supplement, 
and NICE website.6
Base-Case and Comparators
The population had stage 1 primary hypertension without target 
organ damage, established CVD, renal disease, or diabetes.7 In 
the base-case, the model used a starting age of 60 for both 
sexes. Alternative starting ages were chosen to represent the 
treated population for whom data exist (40, 50, 60, 70, and 75) 
and were considered in sensitivity analyses for each CVD risk 
subgroup and sex.6
Antihypertensive drug treatment was compared with no 
antihypertensive drug treatment in four 10-year CVD risk sub-
groups: 5%, 10%, 15%, and 20%. Both treated and untreated 
groups were assumed to receive equal treatment regarding 
other CVD reduction strategies.
Model Structure
The Markov model used a 1-year cycle length and calcu-
lated lifetime costs and QALYs for each comparator (Figure). 
Outcomes included death (either from CVD or non-CVD) and 6 
types of nonfatal CVD events (Data Supplement).
As this was a primary prevention population, all subjects 
entered the model in the no CVD event state. Subsequent 
events occurred depending on risk. For each nonfatal CVD 
event, event and postevent states were used to apply different 
costs and utilities in the first and subsequent cycles (all 1 year). 
Repeat events were not explicitly modeled.
The model was run for a maximum of 60 cycles (to age 
100), by which time most people in the model would have died.
Model Inputs
A summary of the model inputs used in the base-case (primary) 
analysis is provided in Table 1, with further detail in the Data 
Supplement.
Baseline Risks
Annual transition probabilities were calculated for each CVD 
event in the model,8 considering as follows:
• The 10-year CVD risk of the risk subgroup (5%, 10%, 
15%, or 20%), 
• The relative distribution of types of CVD event, 9,10
• How CVD risk changes over time.
Table S1 in the Data Supplement shows the relative distri-
butions of first CVD events by age and sex.
Nonstandard Abbreviations and Acronyms
BP blood pressure
CVD cardiovascular disease
ICER incremental cost-effectiveness ratio
NICE  National Institute for Health and Care 
Excellence
QALY quality-adjusted life-year
SPRINT Systolic Blood Pressure Intervention Trial
Novelty and Significance
What Is New?
• No adequately powered trials have assessed the effec-
tiveness of treatment in stage 1 hypertension (blood 
pressure 140–159/90–99 mm Hg) in low-risk indi-
viduals (<10% 10-year cardiovascular disease risk).
• No previous study has assessed the most cost-effec-
tive risk threshold for starting treatment in people with 
stage 1 hypertension.
• This study used a modeling approach to consider long-
term effectiveness of antihypertensive treatment in 
people with stage 1 hypertension at different levels of 
cardiovascular risk.
What Is Relevant?
• It is cost-effective to treat most people with blood pres-
sure >140/90 mm Hg regardless of risk. The excep-
tion being younger women (<60 years of age) where 
risk calculation is required.
Summary
This newly developed economic model suggests it is 
cost-effective to treat all people aged 60 or more with 
stage 1 hypertension regardless of risk. There is more 
uncertainty in younger people, especially women, how-
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The annual risk of a first CVD event increased by a fixed 
amount each year to account for increasing age. This was applied 
as an additive percentage, with risk calibrated so that the sum of 
the risk of a first event plus the annual increase in risk was equal 
to the 10-year risk when compounded over 10 years.10
Mortality
Non-CVD mortality was estimated using lifetables, applying the 
proportion of noncirculatory deaths to the mortality rates by age 
and sex.11 Mortality after a CVD event was based on standard-
ized mortality ratios (Table 1).
Relative Treatment Effects
Treatment effects were taken from the only systematic review of 
randomised controlled trials identified from the guideline clini-
cal review of stage 1 hypertension (Brunström and Carlberg),12 
adjusted using relative age transformations calculated from 
a meta-analysis of treatment effects (Law et al13; Tables S2 
and S4). Relative risk was assumed constant across all risk 
subgroups, although absolute treatment benefit still varied with 
baseline risk.
Adverse Events
Adverse events were modeled using data from the 
SPRINT (Systolic Blood Pressure Intervention Trial; Data 
Supplement).14–17
Utilities
Baseline quality of life was based on general population esti-
mates stratified by age and sex.18 Quality of life decrements 
associated with CVD events and adverse events were taken 
from the literature, with CVD event utilities applied multiplica-
tively to the general population weights, and adverse event dec-
rements applied as disutilities.8,19,20
Resource Use and Costs
The cost of antihypertensive drug treatment was applied to every-
one alive on treatment and to all following a nonfatal CVD event. 
Drug costs were taken from the British National Formulary for 
the most commonly used drug in each class, taking into account 
variation in the number of drugs prescribed (Table S3).21,22 For 
detailed monitoring costs, see Data Supplement.23–25
The costs of CVD events were identified from the literature 
(Table 1) and inflated to 2016/17 prices.26
Analysis
A lifetime cost-utility analysis was undertaken using a Markov 
model. QALYs and costs from a current UK National Health 
Service and Personal Social Services perspective were consid-
ered, both discounted at 3.5% per annum in line with the NICE 
reference case.3 The model was constructed in Microsoft Excel 
2010 and evaluated by cohort simulation.
QALYs and costs were half-cycle corrected, reflecting the 
assumption that people will transition between states on aver-
age halfway through a cycle. An incremental cost-effectiveness 
ratio (ICER) was calculated as the difference in costs divided by 
the difference in QALYs between the 2 strategies, with results 
presented as cost-per-QALY-gained. The cost-effectiveness of 
antihypertensive treatment was considered in relation to the 
NICE threshold of £20 000 per-QALY-gained.
Figure. Model structure.
CVD indicates cardiovascular disease; 
HF, heart failure; MI, myocardial infarction; 
SA, stable angina; TIA, transient ischemic 
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Table 1. Summary of Base-Case Model Inputs
Input Data Source
Baseline risk
 10-year CVD risk As defined per subgroup  
 Distribution of first CVD events (excluding HF) 3.4%–46.4%; Event, age group, and gender dependent Ward 2005
 HF risk 6.3%–26.1%; Age group and gender dependent Cowie et al9
 Annual increase in risk for CHD Men: 0.03% and Women: 0.008% Ward 2005
 Annual increase in risk for TIA, stroke, HF Increase based on frequency of events relative to CHD 
events
Guideline Committee Consensus
 Non-CV mortality Age and sex dependent Life tables for England, 2014–2016
Proportion of noncirculatory deaths based on Office 
of National Statistics
Standardised mortality ratios
 Stable angina 1.95 (1.65–2.31) Rosengren 1998
 UA 2.19 (2.05–2.33) UA/NSTEMI NICE guideline
 MI 2.68 (2.48–2.91) Bronnum-Hansen 2001
 TIA 1.4 (1.1–1.8) Dennis 1990
 Stroke 2.72 (2.59–2.85) Bronnum-Hansen 2001
 HF 2.20 (1.98–2.42) NICE chronic HF model
Treatment effect (age and sex dependent)
 RR of CHD event (SA, UA, MI) 0.84–0.91 Brunström and Carlberg12 and Law et al13  
 RR stroke/TIA event 0.81–0.93
 RR HF event 0.82–0.94
 RR CV death 0.81–0.92
Adverse events
 Probability of hospitalized AKI 0.003 SPRINT study
 Probability of injurious fall 0.008 SPRINT (AKI substudy)
 Over 75s AKI RR 2.29 SPRINT (AKI substudy)
Costs–drugs and monitoring
 Antihypertensive drugs £16.37–£19.67 (age group and gender dependent) British National Formulary
 GP consultation £37 Personal Social Services Research Unit 2018
 Practice nurse cost £10.85 Personal Social Services Research Unit 2018 and 
2015
 Test costs U&Es: £3.94; Albumine creatinine ratio: £3.33 NHS reference costs 2017/18
 Monitoring—first year (on treatment) £115–£128 (age group and gender dependent) Resource use: guideline committee
Includes consultation and test costs
 Monitoring—subsequent years (on treatment) £75 Clinical Practice Research Datalink
 Monitoring (no treatment), all years £37 Personal Social Services Research Unit 2018
Costs—cardiovascular events and adverse events
 Stroke £23 076 Xu et al23 
 Poststroke £5183




 SA £908 NHS reference costs 2016-17
 Post-SA £273 Assumed same as post-UA








 http://ahajournals.org by on January 4, 2021
ORIGINAL ARTICLE
Constanti et al Treatment Initiation Model
Hypertension. 2021;77:00–00. DOI: 10.1161/HYPERTENSIONAHA.120.14913 February 2021  5
Number needed to treat was calculated using the crude 
average of the relative risk across all events for men and 
women in each age group.
Sensitivity Analyses
Probabilistic sensitivity analysis was undertaken to assess 
parameter uncertainty, with distributions attached to inputs in 
the model where possible (Data Supplement).
Deterministic sensitivity analyses conducted including running 
the model for alternative age groups (probabilistic) and testing dif-
ferential treatment durations in the no treatment group (probabilis-
tic; Table S7).
Other notable (probabilistic) sensitivity analyses around 
treatment effect included:
• Using different treatment effect estimates (Table S8),13
• Adjusting the base-case treatment effect to reflect treat-
ment effect from using >1 drug (Tables S9 and S10).12
Various deterministic sensitivity analyses further tested the 
robustness of model inputs (Data Supplement).
Threshold Analysis
For each age group and sex, the exact risk level (or threshold) 
at which treatment became cost-effective was explored.27,28
RESULTS
Base-Case
For men and women aged 60, antihypertensive treatment 
in stage 1 hypertension was associated with improved 
QALYs but higher costs (Table 2) for all risk thresholds. At 
10% risk, antihypertensive treatment was cost-effective 
for both men (£10 017 [$14 542]/QALY) and women 
(£8635 [$12 536]/QALY) with at least 85% probability 
(Figures S1 through S4). The threshold analysis found 
antihypertensive treatment became cost-effective (at 
£20 000 [$29 035]/QALY) at around 5% for both men 
and women, with significant uncertainty (50% and 51% 
probability cost-effective, respectively).
Results From Other Age Groups (Probabilistic)
A similar pattern was seen in other age groups: as risk 
increased, there were smaller incremental costs and 
higher incremental QALYs, leading to smaller ICERs 
(Table 3).
In all male age groups, and for females age 60 and 
older, treatment regardless of CVD risk was cost-effec-
tive (Table 4).
 Fall £2486 NICE falls guideline; Kenny et al.17 NHS reference 
costs 2017–2018.
 AKI £1885 NHS reference costs 2017–2018
Utilities (age and sex dependent)
 General population utility 0.759–0.895 Health Survey for England 2014
Utility multipliers*
 Well 1 By definition
 SA 0.808 Melsop 2003 
 Post-SA 0.808
 UA 0.770 Goodacre 2004, Ward 2005
 Post-UA 0.880 2008 Lipid modification guideline
 MI 0.760 Goodacre 2004, Ward 2005
 Post-MI 0.880 Tsevat 1993
 TIA 0.900 Lavender 1998 
 Post-TIA 0.900
 Stroke 0.628 Tengs 2003, Youman 2003 
 Poststroke 0.628
 HF 0.683 Davies 2006 
 Post-HF 0.683
 CVD death, non-CVD death 0 By definition
Utility decrements
 Fall −0.343 Peasgood 2009; Applied for 4 weeks
 AKI −0.323 NICE AKI guideline; Applied for 4 weeks
For a full list of sources, see The modeling appendix of the NICE 2019 hypertension guideline: https://www.nice.org.uk/guidance/ng136/evidence. AKI, acute kidney 
injury; CHD, coronary heart disease; CVD, cardiovascular disease; HF, heart failure; MI, myocardial infarction; NHS, National Health Service; NSTEMI, non–ST-segment–
elevation myocardial infarction; RR, relative risk; SA, stable angina; TIA, transient ischemic attack; and UA, unstable angina.
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The number needed to treat to avoid one CVD event 
over 10 years varied from 5 to 79 for men and 7 to 136 
for women (Table S6).
Sensitivity Analyses
The results of the model were sensitive to treatment 
effects. Treating hypertension in lower-risk groups, for 
those age 60, became more cost-effective as the effect 
size increased. Similar (often dominant) results were 
found in older age groups (Tables S12 and S13).
The differential treatment duration analysis (Table 
S11) showed it was cost-effective to treat all people with 
stage 1 hypertension aged 60, regardless of how soon 
they became eligible for treatment from other reasons 
(Data Supplement for discussion of other age groups).
Varying inputs that favored treatment or reduced costs 
led to lower ICERs, for example, more favorable treat-
ment effect, or having no serious adverse events (Table 
S14). Conversely, as expected, varying inputs that would 
bias against treatment led to increased ICERs.
DISCUSSION
Summary of Main Results
This economic model has shown it is generally cost-
effective to treat stage 1 hypertension with antihy-
pertensive drugs in all men (regardless of age) and 
all women (aged 60 or over). In younger women, the 
population risk profile was such that some would not 
reach the minimum threshold above which treatment 
was cost-effective, suggesting individual risk calcula-
tion might be appropriate.
Results were generally robust to sensitivity analy-
ses. The differential treatment duration analysis for the 
base-case age showed it remained cost-effective to treat 
all those aged 60 with stage 1 hypertension. The cost-
effectiveness of treatment for younger men depended 
on whether they would become eligible for antihyper-
tensive treatment within around 20 years. It was still not 
cost-effective to treat all younger women, regardless of 
durations tested. The model was most sensitive to treat-
ment effect, where more favorable treatment effects 
resulted in ICERs for all age/sex/risk groups that were 
either very low or treatment was dominant.
Comparison With Literature
To our knowledge, this is the first economic evaluation 
of initiating treatment in different CVD risk groups in this 
patient population.
The model was based on a recent meta-analysis of 
the efficacy of antihypertensive drug treatment in primary 
prevention by BP group, of which stage 1 hypertension 
was one.12 The total included population had an average 
age of 63 and average systolic BP 154 mm Hg. For those 
only with stage 1 hypertension, the patient characteristics 
were not summarized, however, as the majority of trials 
labeled as primary prevention included some populations 
with comorbidities (eg, diabetes), the average CVD risk 
could be higher than a truly low-risk population.
Results for the lower-risk subgroups in the model need 
to be interpreted with caution. An observational study 
of antihypertensive treatment in a moderate risk group, 
using UK primary care data over a median follow-up 
period of 5.8 years, found no benefit of antihypertensive 
treatment for mortality (hazard ratio, 1.02 [0.88–1.17]) 
or CVD events (hazard ratio, 1.09 [0.95–1.25]) and an 
increased risk of adverse events.29
Other studies have used different methods to assess 
thresholds for initiating antihypertensive treatment. 











CE at £20 000
Risk 
threshold
 Male  Female  
5% risk 5.02% 5% risk 4.94%
 No Tx £2910 12.93  50% £3346 13.17  49%
 Tx £4034 12.99 £20 524* 50% £4465 13.23 £19 978 51%
10% risk 10% risk
 No Tx £4169 12.52  15% £5241 12.73  12%
 Tx £5105 12.61 £10 017 85% £6092 12.83 £8635 88%
15% risk 15% risk
 No Tx £5348 12.14  6% £6991 12.33  5%
 Tx £6107 12.26 £5969 94% £7602 12.46 £4610 95%
20% risk 20% risk
 No Tx £6443 11.78  3% £8621 11.96  3%
 Tx £7062 11.93 £3993 97% £9035 12.12 £2566 97%
*Values above the NICE cost-effectiveness threshold of £20 000/QALY. Risk thresholds based on deterministic results. CE indicates cost-effective; ICER, incremental 
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Another systematic review (Ettehad et al 2016) found a 
benefit for treatment on the basis of risk below 140/90 
mm Hg.30 However, the review included populations with 
CVD, so outcomes were more representative of second-
ary rather than primary prevention.
The results for those receiving no treatment were vali-
dated using UK life tables and were consistent, suggest-
ing that the assumptions used here were appropriate.11
Limitations of the Model
The model was considered conservative for various rea-
sons, including the structural assumption that people on 
no treatment would never commence antihypertensive 
treatment, unless they had a CVD event. This assumption 
was tested in sensitivity analyses, which did not change 
the conclusions in younger women but implied that risk 
assessment would be helpful in younger men who might 
become eligible for treatment for other reasons within 20 
years. This reinforced the uncertainty around treatment 
thresholds for younger people, who are likely to have lower 
risk, and for whom 10-year risk calculators underestimate 
lifetime CVD risk.31,32 Furthermore, vascular damage in 
younger individuals may be preventable but irreversible 
later in life.33 Other possible benefits from taking anti-
hypertensive treatment such as a possible reduction in 
dementia would also underestimate treatment benefit.34,35
The model was also conservative by not modeling 
repeat CVD events. This reduced complexity and data 
requirements. Health state costs that included future 
event costs were used wherever possible. However, if 
avoiding one event from treatment also avoided future 
events, it is likely that including repeat events would have 
made treatment more cost-effective.
Treatment effects used were conservative as they 
were mostly derived from studies of single drug inter-
ventions.12 Sensitivity analyses suggested more favor-
able treatment effects would make treatment more 
cost-effective in all groups. However, little data were 
available from truly lower-risk people with stage 1 
hypertension, as such individuals are rarely included in 
RCTs.29 This reinforced the uncertainty about the most 













CE at 20 000
 Male Female
Age 60 (base-case)
 5% £1124 0.05 £20 524* 50% £1119 0.06 £19 978 51%
 10% £935 0.09 £10 017 85% £851 0.10 £8635 88%
 15% £760 0.13 £5969 94% £611 0.13 £4610 95%
 20% £619 0.16 £3993 97% £414 0.16 £2566 97%
Age 40
 5% £866 0.13 £6889 95% £794 0.11 £7077 95%
 10% £583 0.18 £3198 99% £332 0.18 £1829 99%
 15% £340 0.22 £1517 100% -£45 0.23 Dominant† 100%
 20% £156 0.25 £613 100% -£351 0.27 Dominant† 100%
Age 50
 5% £998 0.09 £10 643 84% £959 0.09 £11 228 84%
 10% £743 0.15 £5042 97% £590 0.14 £4178 97%
 15% £537 0.19 £2851 99% £288 0.19 £1550 99%
 20% £360 0.22 £1621 100% £44 0.22 £199 100%
Age 70
 5% £989 0.02 £41 532* 9% £1000 0.03 £32 066* 19%
 10% £870 0.04 £19 667 52% £829 0.06 £14 563 67%
 15% £762 0.06 £12 379 73% £674 0.08 £8445 82%
 20% £661 0.08 £8569 83% £534 0.10 £5369 88%
Age 75
 5% £881 0.02 £54 318 1% £903 0.02 £38 587 8%
 10% £780 0.03 £23 475 40% £752 0.05 £16 155 64%
 15% £692 0.05 £14 417 68% £614 0.07 £9253 82%
 20% £606 0.06 £9887 80% £498 0.08 £5992 88%
*Values above NICE cost-effectiveness threshold of £20 000/QALY. †Treatment is a dominant intervention (more effective and less expensive). CE indicates cost-
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appropriate treatment threshold in younger-/lower-risk 
people due to the assumption of constant relative ben-
efit across risk subgroups.29 However, the risk thresh-
olds tested were close to the feasible risk levels, and so 
antihypertensive treatment is likely to be cost-effective 
for those with additional risk factors and stage 1 hyper-
tension. As 87% of UK adults have at least one risk 
factor, and around half have 2 or more, on balance, it 
may be cost-effective to treat stage 1 hypertension in 
the majority of the population.36
The underlying risk used in the model is not affected 
by the calculation method and, therefore, would be gen-
eralizable to other settings, providing costs were similar. 
Specifically, the performance of the US atherosclerotic 
CVD risk calculator is similar to the UK QRISK2 calcula-
tor (used in this study)37 and would give equivalent out-
comes.38 Similarly, using QRISK3, which predicts slightly 
lower risks for each age, would have little effect on the 
interpretation of the results.39
Another factor not considered was the variability in 
CVD risk over time, which was assumed to increase lin-
early, but might increase at a faster rate at certain time 
points, particularly in older people.40 This would increase 
the absolute benefit from treatment in those age groups. 
However, as older people have a much higher risk, treat-
ing older people regardless of risk was shown to be 
cost-effective.
A 1-year cycle length was chosen, and although a 
shorter cycle length can reduce the error of estimates 
produced, such benefits are modest with a lifetime hori-
zon in a low-risk population, and bring significant compu-
tational burden. Furthermore, half-cycle correction was 
applied to improve precision.
In the model, utility decrements for adverse events 
were assumed to be additive. However, where lower 
quality of life is due to other comorbidities, this may have 
differential influences on quality of life from side effects.
Alternative modeling approaches such as micro-
simulation were considered. This could have improved 
the precision of population estimates. However, micro-
simulation would have added complexity and significant 
computational burden, with little clear benefit overall. In 
addition, the model structure was shared with the NICE 
lipid modification guideline,8 allowing for consistency in 
methods in CVD prevention models, facilitating consis-
tency in interpretation.
Finally, adherence to treatment with antihypertensive 
drugs may differ between clinical trials and the real-
world, leading to an overestimation of the treatment 
effect.41 However, there is insufficient published data to 
model the effect of adherence to antihypertensive drugs 
therapy on CVD events without excessive assumptions, 
which risk invalidating the model; this approach is consis-
tent with other models.8 Any impact for suboptimal drug 
adherence is likely to be mitigated by the numerous con-
servative assumptions already described.
Clinical Implications
The model supports a recommendation to lower the CVD 
risk threshold for antihypertensive treatment to 10% in 
stage 1 hypertension, with considerable uncertainty of 
benefit below that. This contrasts US and European guid-
ance to treat all people with BP >140/90 mm Hg regard-
less of risk. This discrepancy can largely be explained by 
differing interpretation of the SPRINT results.42
Extrapolating the conclusions of this model to other 
health care systems is dependent on the costs of drug 
treatment, CVD risks, and adverse event rates in those 
settings. If treatment of CVD events was more expensive 
relative to antihypertensive treatment (as for example in 
the United States), antihypertensive treatment would be 
more cost-effective.43 Treatment of all stage 1 hyperten-
sion in high-cost settings may, therefore, be appropriate.
Perspectives
This analysis found that treating people with stage 1 
hypertension (without target organ damage, estab-
lished CVD, renal disease, or diabetes) regardless of 
CVD risk was cost-effective across most age and sex 
subgroups, the exception being women under 60. The 
conclusions were sensitive to assumptions related to 
treatment efficacy and also differential initiation of 
treatment. Overall, antihypertensive treatment for indi-
viduals aged 60 or over with stage 1 hypertension is 
cost-effective in the UK National Health Service, but 
below this age, cost-effectiveness depends on CVD 
risk and how quickly an individual develops other 
indications for treatment. In these younger popula-
tions, additional potential benefits of antihypertensive 
Table 4. Model Interpretation Based on Cardiovascular Risk
Age
 










 40 0.7% 1.50% Treat all
 50 1.8% 4.00% Treat all
 60 5.0% 8.50% Treat all
 70 9.7% 16.40% Treat all
 75 11.4% 22% Treat all
Female
 40 1.7% 0.90% Treat above 1.7% risk
 50 2.8% 2.30% Treat above 2.8% risk
 60 4.9% 5.30% Treat all
 70 7.5% 11.70% Treat all
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treatment were not captured by the model and should 
be considered in making treatment decisions.44
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